SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Bio-Rad Labs: Things are changing

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dave Chanoux who wrote (2)1/29/2000 9:33:00 PM
From: Dave Chanoux  Read Replies (2) of 18
 
Time to get into quantitative data:

Here is a brief history of Bio-Rad quarterly revenue and eps
for 1998 and 1999 (first 3 quarters). Conclusion: not much
of a trend here.

1999 | 1998
Revenue EPS | Revenue EPS
3/31 $126M .89 | $116 M .89
6/30 116 .65 | 108 .58
9/30 113 .35 | 99 .16
12/31 ? ? | 119 .52

My sources: Company reports; Value-Line Investment Survey.

The real question is where do we go from here?

Not too many analysts cover Bio-Rad Laboratories. I have
found data published by the Value Line Investment Survey.
Here is the Value Line projection for year 2000 made before
and after the Sanofi Diagnostic Pasteur acquisition:

Including SDP Without SDP
2000 | 2000
Revenue EPS | Revenue EPS
3/31 $180M .50 | $132 M .89
6/30 175 .35 | 122 .70
9/30 165 .15 | 113 .31
12/31 185 .40 | 138 .65
Total 705 1.40 505 2.55

Difference: $200M (1.15)

Wait, how can this be? $200 M incremental revenue, operating at a loss.

This is the question and the opportunity. Is this really
a loss, funny accounting, analysts short-term myopia,
front end cost loading, amortization of goodwill?

What's going on here?

Regards,
Dave Chanoux
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext